ZA847350B - An occlusion compound of 2-nitroxymethyl-6-chloropyridine with beta-cyclodextrin and process for preparation thereof - Google Patents

An occlusion compound of 2-nitroxymethyl-6-chloropyridine with beta-cyclodextrin and process for preparation thereof

Info

Publication number
ZA847350B
ZA847350B ZA847350A ZA847350A ZA847350B ZA 847350 B ZA847350 B ZA 847350B ZA 847350 A ZA847350 A ZA 847350A ZA 847350 A ZA847350 A ZA 847350A ZA 847350 B ZA847350 B ZA 847350B
Authority
ZA
South Africa
Prior art keywords
nitroxymethyl
chloropyridine
cyclodextrin
beta
preparation
Prior art date
Application number
ZA847350A
Other languages
English (en)
Inventor
Yoshio Ueda
Fumio Shimojo
Kiyoshige Yoshida
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of ZA847350B publication Critical patent/ZA847350B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
ZA847350A 1983-10-11 1984-09-18 An occlusion compound of 2-nitroxymethyl-6-chloropyridine with beta-cyclodextrin and process for preparation thereof ZA847350B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP58190345A JPS6081166A (ja) 1983-10-11 1983-10-11 2−ニトロオキシメチル−6−クロロピリジンのβ−シクロデキストリン包接化合物およびその製造法

Publications (1)

Publication Number Publication Date
ZA847350B true ZA847350B (en) 1985-10-30

Family

ID=16256648

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA847350A ZA847350B (en) 1983-10-11 1984-09-18 An occlusion compound of 2-nitroxymethyl-6-chloropyridine with beta-cyclodextrin and process for preparation thereof

Country Status (18)

Country Link
US (1) US4575548A (xx)
EP (1) EP0141300A3 (xx)
JP (1) JPS6081166A (xx)
KR (1) KR850003414A (xx)
CN (1) CN85102133A (xx)
AU (1) AU576521B2 (xx)
CA (1) CA1248523A (xx)
DK (1) DK461184A (xx)
ES (1) ES536654A0 (xx)
FI (1) FI843944L (xx)
GR (1) GR80531B (xx)
HU (1) HU194285B (xx)
IL (1) IL73076A (xx)
NO (1) NO843773L (xx)
OA (1) OA07832A (xx)
PH (1) PH20203A (xx)
PT (1) PT79320B (xx)
ZA (1) ZA847350B (xx)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6034156A (ja) * 1983-08-08 1985-02-21 Hayashibara Biochem Lab Inc エイコサペンタエン酸包接化合物及びこれを含有した飲食物
JPS60202115A (ja) * 1984-03-27 1985-10-12 Ichiro Shibauchi エポキシ樹脂用硬化剤
ZA885069B (en) * 1987-07-24 1989-03-29 Fujisawa Pharmaceutical Co Sustained-release percutaneous preparations
US5017566A (en) * 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
CA1321192C (en) * 1988-04-20 1993-08-10 Abdul Majid Inclusion complexes of cyclodextrins by agglomeration
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US20040014695A1 (en) * 1992-06-19 2004-01-22 Supergen, Inc. Pharmaceutical formulation
US5602112A (en) * 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US5824668A (en) * 1996-11-07 1998-10-20 Supergen, Inc. Formulation for administration of steroid compounds
EP1176792A1 (en) * 2000-07-24 2002-01-30 Alcatel Method and apparatus for providing an all digital loop with power-optimised mode
US20070010485A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070010466A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
US20070010487A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070009532A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar
US20070010486A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US11812951B2 (en) 2008-06-17 2023-11-14 Apollo Endosurgery Us, Inc. Endoscopic needle assembly
CA2692211C (en) * 2009-12-14 2011-09-13 Cellresin Technologies, Llc Maturation or ripening inhibitor release from polymer, fiber, film, sheet or packaging
CA2831213C (en) 2011-03-27 2016-05-17 Cellresin Technologies, Llc Cyclodextrin compositions, articles, and methods
US10182567B2 (en) 2011-03-27 2019-01-22 Cellresin Technologies, Llc Cyclodextrin compositions, articles, and methods
US9320288B2 (en) 2012-11-30 2016-04-26 Cellresin Technologies, Llc Controlled release compositions and methods of using
US9421793B2 (en) 2014-06-26 2016-08-23 Cellresin Technologies, Llc Electrostatic printing of cyclodextrin compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2959580A (en) * 1956-10-17 1960-11-08 Univ Minnesota Formation of inclusion compounds
CH445129A (fr) * 1964-04-29 1967-10-15 Nestle Sa Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé
JPS56123912A (en) * 1980-03-05 1981-09-29 Nitto Electric Ind Co Ltd Drug-containing tape preparation
HU182217B (en) * 1980-10-17 1983-12-28 Chinoin Gyogyszer Es Vegyeszet Process for producing inclusive complexes of cyclodextrines and strong inorganic oxyacids
JPS57142962A (en) * 1981-02-28 1982-09-03 Santen Pharmaceut Co Ltd Cyclodextrin clathrate compound of sulfur-containing compound
JPS6054304B2 (ja) * 1981-10-16 1985-11-29 株式会社バコム ジソピラミド包接化合物
US4425336A (en) * 1982-05-24 1984-01-10 Key Pharmaceuticals, Inc. 3,4-Dihydroxy-N-[3-(4-dihydroxyphenyl)-1-methyl-n-propyl]-beta-phenethylamine cyclodextrin complexes
DK311683A (da) * 1982-07-26 1984-01-27 Fujisawa Pharmaceutical Co Fremgangsmaade til fremstilling af pyridylalkylnitratforbindelser
JPS6025967A (ja) * 1983-07-21 1985-02-08 Eisai Co Ltd トリパミド包接化合物
DE3329517A1 (de) * 1983-08-16 1985-02-28 Hoechst Ag, 6230 Frankfurt Einschlussverbindung von n,n-dimethyl-2-chlor-5-(3-methyl-2-(phenylimino)-4-thiazolin-4-yl)phenylsulfonamid, verfahren zu ihrer herstellung sowie pharmazeutische praeparate
DE3337802A1 (de) * 1983-10-18 1985-04-25 Merck Patent Gmbh, 6100 Darmstadt Pharmazeutische zubereitung

Also Published As

Publication number Publication date
PT79320A (en) 1984-11-01
CN85102133A (zh) 1987-01-17
AU576521B2 (en) 1988-09-01
OA07832A (fr) 1986-11-20
PT79320B (en) 1986-09-08
ES8506758A1 (es) 1985-08-01
NO843773L (no) 1985-04-12
FI843944L (fi) 1985-04-12
JPS6245226B2 (xx) 1987-09-25
GR80531B (en) 1985-01-09
US4575548A (en) 1986-03-11
CA1248523A (en) 1989-01-10
EP0141300A3 (en) 1986-01-29
KR850003414A (ko) 1985-06-17
AU3339984A (en) 1985-04-18
ES536654A0 (es) 1985-08-01
FI843944A0 (fi) 1984-10-08
EP0141300A2 (en) 1985-05-15
JPS6081166A (ja) 1985-05-09
HU194285B (en) 1988-01-28
DK461184D0 (da) 1984-09-26
DK461184A (da) 1985-04-12
PH20203A (en) 1986-10-20
IL73076A (en) 1988-05-31
HUT36832A (en) 1985-10-28
IL73076A0 (en) 1984-12-31

Similar Documents

Publication Publication Date Title
ZA847350B (en) An occlusion compound of 2-nitroxymethyl-6-chloropyridine with beta-cyclodextrin and process for preparation thereof
DE3477929D1 (en) Beta-cyclodextrin and process for its preparation
GB2151647B (en) Process for the preparation of cyclodextrins
DE3470737D1 (en) 2-aminonitropyridine derivatives and process for the preparation thereof
ZA843249B (en) Compound body and method of making the same
PT78195A (en) Process for the preparation of imidazolines and related compounds
PH21087A (en) Dibenzodiazepin derivatives and process for their preparation
DE3460031D1 (en) Process for the preparation of 4-chloro-phenyl-sulphonyl-compounds
DE3376979D1 (en) 3-methylflavone-8-carboxylic acid derivatives and process for the preparation of the same
DE3479494D1 (en) Prostacyclines and process for their preparation
GB2146028B (en) Spf-100 and process for the preparation thereof
DE3469024D1 (en) Process for the preparation of n-alkylphthalimide and copolymer derived therefrom
GB2146016B (en) Method for the preparation of haloacetals and halodioxolanes
GB2145722B (en) Process for the preparation of 6-demethyl-6-deoxy-6-methylene-5-oxytetracyclin and the 11a-chloro-derivative thereof
DE3461078D1 (en) Process for the preparation of diacyloxybutenes
DE3461470D1 (en) Process for the preparation of polycumylene
GR80985B (en) Benzaldehyde derivative and process for its preparation
DE3460344D1 (en) Process for the preparation of 5-chloro-2-aminophenol
DE3469895D1 (en) Process for the preparation of 2-acetylamino-6-nitro-benzothiazole and 2-amino-6-nitro-benzothiazole
DE3361867D1 (en) 3-propionylsalicyclic acid derivatives and process for the preparation of the same
DE3470541D1 (en) Tetrahydro-beta-carboline derivatives and process for the preparation thereof
DE3367383D1 (en) Process for the preparation of bromoanthraquinones
DE3465195D1 (en) Process for the preparation of 6-methylpyridone-2
DE3462505D1 (en) Process for the preparation of dimethylsilyldicyanide
HRP931253A2 (en) Process for the preparation of athenolole and the derivatives thereof